Journal
CANCERS
Volume 12, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/cancers12082033
Keywords
lymphovascular invasion; pancreatic cancer; TCGA
Categories
Funding
- National Institute of Health (NIH) [R01CA160688]
- National Cancer Institute (NCI) [P30CA016056, U24CA232979]
- NCI [U24 CA180921]
Ask authors/readers for more resources
Lymphovascular invasion (LVI) is an aggressive pathologic feature and considered a risk factor for distant metastasis. We hypothesized that pancreatic ductal adenocarcinomas (PDACs) with LVI are associated with shorter survival, as well as aggressive cancer biology and lymphangiogenesis in transcriptomic analysis. Utilizing the cancer genome atlas (TCGA)-PDAC cohort, we found that positive LVI was significantly associated with positive perineural invasion (PNI) (p= 0.023), and higher American Joint Committee on Cancer (AJCC) T (p= 0.017) and N (p< 0.001) categories. Furthermore, positive LVI was associated with shorter overall survival (OS) (p= 0.014) and was an independent risk factor of poor OS. Although there was no association between LVI status and lymphangiogenesis, epithelial-mesenchymal transition (EMT), or metastasis-related genes, Gene Set Enrichment Analysis revealed a strong association with cell-proliferation-related gene sets such as mitotic spindles (Normalized enrichment score (NES) = 1.76,p= 0.016) and G2/M checkpoints (NES = 1.75,p= 0.036), as well as with transforming growth factor beta (TGF-beta) signaling (NES = 1.61,p= 0.043), which is a known mechanism of metastasis in PDACs. In conclusion, positive LVI was an independent risk factor of poor OS in PDACs. We found that PDACs with LVI were possibly associated with accelerated cell proliferation and enhanced TGF-beta signaling independent of lymphangiogenesis. Transcriptomic profiling elucidates more precise tumor biology of LVI-positive PDACs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available